Pharmacogenetics of human cytosolic sulfotransferases
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Cytosolic sulfotransferases (SULTs) are phase II detoxification enzymes that are involved in the biotransformation of a wide variety of structurally diverse endo- and xenobiotics, including many therapeutic agents and endogenous steroids. Single-nucleotide polymorphisms (SNPs) in SULTs have functional consequences on the translated protein. For the most part, these SNPs are fairly uncommon in the population, but some, most notably for SULT isoform 1A1, are commonly found and have been associated with cancer risk for a variety of tumor sites and also with response to therapeutic agents. SNPs in the hydroxysteroid sulfotransferase, SULT2A1, have been identified in African-American subjects and influence the ratio of plasma DHEA:DHEA-S. This modification could potentially influence cancer risk in steroidogenic tissues. SNPs in many SULTs are ethnically distributed, another factor that could influence SULT pharmacogenetics. Finally, genetic variation has also been identified in 3'-phosphoadenoside 5'-phosphosulfate synthetase (PAPPS), the enzymes responsible for producing the obligatory cosubstrate for all sulfotransferases. Taken together, this variability could substantially influence the disposition of drugs metabolized by SULTs. Elucidation of the basis and effect of variability in sulfation could greatly impact individualized therapy in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“African-Americans have a high rate of polymorphisms in SULT2A1 apparently influencing plasma ratios of DHEA: DHEAS, which may correlate with the risk of prostatic and other cancers (603).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [603]
Citations
Cites
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129 · cited 1×
“Tamoxifen has been the gold standard of endocrine therapy for breast cancer since the 1970s (1985; 1986; Mariotto et al., 2002) and its use has contributed significantly to the decline in breast cancer mortality (Love et al., 1992).”
BackgroundSulfotransferases in the bioactivation of xenobiotics
Glatt, H. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00202-7 · Cited by 354 · cited 1×
“To date, at least 11 different SULT enzymes have been identified (reviewed in Glatt, 2000).”
BackgroundThe effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women
MORTOLA, J. F., & YEN, S. S. C. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-3-696 · Cited by 311
Raftogianis, R. B., Wood, T. C., Otterness, D. M., Van Loon, J. A., & Weinshilboum, R. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7466 · Cited by 305 · cited 1×
“These SNPs were in linkage disequilibrium with each other and with an SNP at 638, which is responsible for an aminoacid change from arginine to histidine at residue 213 (Raftogianis et al., 1997; Ozawa et al., 1998).”
BackgroundTyrosine Sulfation and the Secretory Pathway
Huttner, W. B. (1988) · Annual Review of Physiology · doi:10.1146/annurev.ph.50.030188.002051 · Cited by 263 · cited 1×
“SULTs involved in Phase II biotransformation of endoand xenobiotics are cytosolic, although there are membrane bound SULTs that are responsible for catalysing the sulfation of protein tyrosyl residues and polysaccharides (Huttner, 1988; Hashimoto and Hirschberg, 1992).”
BackgroundGenotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Wegman, P., Vainikka, L., Stål, O., Nordenskjöld, B., Skoog, L., Rutqvist, L.-E., & Wingren, S. (2005) · Breast Cancer Research · doi:10.1186/bcr993 · Cited by 243 · cited 1×
“A subsequent study in the context of a clinical trial also indicated the same trend of better overall survival associated with the SULT1A1*1 allele (Wegman et al., 2005) in patients treated with tamoxifen.”
ResultAdjuvant Chemotherapy for Breast Cancer
BLOMQVIST, C. P. (1985) · JAMA · doi:10.1001/jama.1985.03360240073038 · Cited by 237
Pharmacogenetics of Sulfotransferase
Nagata, K., & Yamazoe, Y. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.159 · Cited by 215 · cited 1×
“SULT pharmacogenetics have been the subject of two recent reviews (Nagata and Yamazoe, 2000; Glatt and Meinl, 2004).”
BackgroundKhetawat, G., Faraday, N., Nealen, M. L., Vijayan, K. V., Bolton, E., Noga, S. J., & Bray, P. F. (2000) · Blood · doi:10.1182/blood.v95.7.2289 · Cited by 210
Parker, C. R. (1999) · Steroids · doi:10.1016/s0039-128x(99)00046-x · Cited by 201 · cited 1×
“Humans synthesize large amounts of DHEA-sulfate during fetal development and after adrenarche (Parker, 1999).”
BackgroundSteroid sulfation by expressed human cytosolic sulfotransferases
Falany, C. N., Wheeler, J., Oh, T. S., & Falany, J. L. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90077-9 · Cited by 177 · cited 6×
“OH TAM (Falany et al., 1994b) and endoxifen (unpublished data).”
BackgroundInfluentialSelf-citationNowell, S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.21.1635 · Cited by 160 · cited 1×
“…of breast cancer in patients receiving tamoxifen therapy was examined, there was a strong association between survival and the SULT1A1*1 common allele, contrary to the expected outcome if higher activity did in fact result in rapid removal of the drug from the target tissue (Nowell et al., 2002).”
ResultSelf-citationArlt, W., Haas, J., Callies, F., Reincke, M., Hübler, D., Oettel, M., Ernst, M. E., Schulte, H. M., & Allolio, B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.2170 · Cited by 158
Pharmacogenetics of soluble sulfotransferases (SULTs)
Glatt, H. R., & Meinl, W. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0826-0 · Cited by 153 · cited 2×
“SULT pharmacogenetics have been the subject of two recent reviews (Nagata and Yamazoe, 2000; Glatt and Meinl, 2004).”
BackgroundCampbell, N. R. C., Loon, J. A. V., & Weinshilboum, R. M. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90108-0 · Cited by 122 · cited 1×
“SULT1A1 is expressed in blood platelets, and platelet activity has been demonstrated to correlate with activities in other tissues (Young et al., 1985; Campbell et al., 1987; Sundaram et al., 1989a).”
BackgroundFALANY, C. N., COMER, K. A., DOOLEY, T. P., & GLATT, H. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb17372.x · Cited by 110 · cited 1×
“SULT2A1 is the major SULT isoform involved in the formation of steroid sulfate esters and is capable of sulfating both 3a- and 3b-hydroxysteroids, estrogens, testosterone and aliphatic hydroxyl-containing drugs and xenobiotics (Falany et al., 1995).”
BackgroundSelf-citationNishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., Muro, K., & Watabe, T. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00994-2 · Cited by 109 · cited 5×
“OH TAM (Falany et al., 1994b) and endoxifen (unpublished data).”
InfluentialOzawa, S., Tang, Y.-M., Yamazoe, Y., Kato, R., Lang, N. P., & Kadlubar, F. F. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00135-x · Cited by 96 · cited 1×
“These SNPs were in linkage disequilibrium with each other and with an SNP at 638, which is responsible for an aminoacid change from arginine to histidine at residue 213 (Raftogianis et al., 1997; Ozawa et al., 1998).”
BackgroundHuman sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies
Thomae, B. A., Eckloff, B. W., Freimuth, R. R., Wieben, E. D., & Weinshilboum, R. M. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500089 · Cited by 94 · cited 3×
“The allelic frequencies reported by Thomae et al. (2002) in 120 alleles from the Coriell Cell Repositorty are shown in Table 3.”
MethodResultInfluentialNowell, S. A., Ambrosone, C. B., Ozawa, S., MacLeod, S. L., Mrackova, G., Williams, S. P., Plaxco, J., Kadlubar, F. F., & Lang, N. P. (2000) · Pharmacogenetics · doi:10.1097/00008571-200012000-00004 · Cited by 91 · cited 2×
“Some studies have shown that SULT1A1 platelet enzymatic activity varies by gender and by season (Marazziti et al., 1995, 1998; Nowell et al., 2000).”
BackgroundSelf-citationCharacterization of thyroid hormone sulfotransferases
Visser, T. J., Kaptein, E., Glatt, H. R., Bartsch, I., Hagen, M., & Coughtrie, M. W. H. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00139-7 · Cited by 90 · cited 1×
“…highly expressed hepatic sulfotransferase and this isoform has been reported to sulfate a wide variety of phenolic xenobiotics, as well as iodothyronines (Visser et al., 1998; Kester et al., 1999; Li et al., 2001) and the antiangiogenic estrogen metabolite, 2-methoxyestradiol (Spink et al., 2000).”
BackgroundCharacterization of Human Iodothyronine Sulfotransferases1
Kester, M. H. A., Kaptein, E., Roest, T. J., van Dijk, C. H., Tibboel, D., Meinl, W., Glatt, H., Coughtrie, M. W. H., & Visser, T. J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5590 · Cited by 88
Xu, Z.-H., Otterness, D. M., Freimuth, R. R., Carlini, E. J., Wood, T. C., Mitchell, S. R., Moon, E., Kim, U.-J., Xu, J.-P., Siciliano, M. J., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2123 · Cited by 76 · cited 1×
“These two enzymes differ in their tissue distribution, with PAPPS-1 mRNA found abundantly in brain and PAPPS-2 highly expressed in the liver (Xu et al., 2000).”
BackgroundProjecting SEER cancer survival rates to the US: an ecological regression approach
Mariotto, A. B., Capocaccia, R., Verdecchia, A., Micheli, A., Feuer, E. J., Pickle, L. W., & Clegg, L. X. (2002) · Cancer Causes & Control · doi:10.1023/a:1014380323037 · Cited by 67 · cited 1×
“Tamoxifen has been the gold standard of endocrine therapy for breast cancer since the 1970s (1985; 1986; Mariotto et al., 2002) and its use has contributed significantly to the decline in breast cancer mortality (Love et al., 1992).”
BackgroundRegulation of estrogen activity by sulfation in human Ishikawa endometrial adenocarcinoma cells
Kotov, A., Falany, J. L., Wang, J., & Falany, C. N. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00022-9 · Cited by 66 · cited 1×
“…occurs at physiological concentrations, but while SULT1A1 is capable of sulfating other estrogens at micromolar concentrations (Falany et al., 1994a), SULT1E1 is responsible for the regulation of estrogen responsiveness at physiological concentrations (Falany et al., 1998; Kotov et al., 1999).”
BackgroundSelf-citationLiyou, N. E., Buller, K. M., Tresillian, M. J., Elvin, C. M., Scott, H. L., Dodd, P. R., Tannenberg, A. E. G., & McManus, M. E. (2003) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540305101209 · Cited by 66 · cited 1×
“A third, less characterized subfamily of brain-specific SULT has also been described (Liyou et al., 2003).”
BackgroundBesset, S., Vincourt, J.-B., Amalric, F., & Girard, J.-P. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.2.345 · Cited by 63 · cited 3×
“The pattern of expression of these isoforms differ according to the tissue examined and it has been shown that subcellular localization can depend on coexpression of the two isoforms (Besset et al., 2000).”
BackgroundIdentification and characterization of cytosolic sulfotransferases in normal human endometrium
Falany, J. L., Azziz, R., & Falany, C. N. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00143-9 · Cited by 62 · cited 1×
“…occurs at physiological concentrations, but while SULT1A1 is capable of sulfating other estrogens at micromolar concentrations (Falany et al., 1994a), SULT1E1 is responsible for the regulation of estrogen responsiveness at physiological concentrations (Falany et al., 1998; Kotov et al., 1999).”
BackgroundSelf-citationHuman platelet phenol sulfotransferase: Familial variation in thermal stability of the TS form
Loon, J. V., & Weinshilboum, R. M. (1984) · Biochemical Genetics · doi:10.1007/bf00499627 · Cited by 58 · cited 1×
“However, SULT1A1 activity varies several-fold among individuals and shows a strong familial segregation (Van Loon and Weinshilboum, 1984).”
BackgroundConsensus conference. Adjuvant chemotherapy for breast cancer
(1985) · JAMA · doi:10.1001/jama.254.24.3461 · Cited by 58
Sulfotransferase pharmacogenetics
Weinshilboum, R. M. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90010-y · Cited by 54
Human Phenol Sulfotransferase: Correlation of Brain and Platelet Activities
Young, W. F., Laws, E. R., Sharbrough, F. W., & Weinshilboum, R. M. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb08734.x · Cited by 52 · cited 1×
“SULT1A1 is expressed in blood platelets, and platelet activity has been demonstrated to correlate with activities in other tissues (Young et al., 1985; Campbell et al., 1987; Sundaram et al., 1989a).”
BackgroundCappiello, M., Franchi, M. P., Giuliani, L., & Pacifici, G. M. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00679793 · Cited by 50 · cited 1×
“SULT enzymes have a widespread tissue distribution and are expressed in the liver, lung, brain, skin, platelets, breast, kidney and gastrointestinal tissue (Cappiello et al., 1989; Zou et al., 1990; Kudlacek et al., 1995; Falany and Falany, 1996; Hume et al., 1996).”
BackgroundHempel, N., Wang, H., LeCluyse, E. L., McManus, M. E., & Negishi, M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003350 · Cited by 50 · cited 1×
“Human SULT1A1 lacks a TATA-box and recent examination of the promoter region has shown that promoter activity is dependent on the presence of SP-1 and Ets transcription factor binding sites, which are located 112 bp upstream of the transcription start site (Hempel et al., 2004).”
BackgroundSULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells
Spink, B. C. (2000) · Carcinogenesis · doi:10.1093/carcin/21.11.1947 · Cited by 49 · cited 1×
“…highly expressed hepatic sulfotransferase and this isoform has been reported to sulfate a wide variety of phenolic xenobiotics, as well as iodothyronines (Visser et al., 1998; Kester et al., 1999; Li et al., 2001) and the antiangiogenic estrogen metabolite, 2-methoxyestradiol (Spink et al., 2000).”
BackgroundSulfation pharmacogenetics in humans
Weinshilboum, R. M., & Aksoy, I. A. (1994) · Chemico-Biological Interactions · doi:10.1016/0009-2797(94)90066-3 · Cited by 47 · cited 1×
“Previously, human platelets have been employed as a source of enzyme for human pharmacogenetic studies due to their expression of two of the most common SULTs, SULT1A1 and SULT1A3 (Sundaram et al., 1989b; Weinshilboum, 1990; Weinshilboum and Aksoy, 1994).”
MethodThe Estrogen Receptor Is Present in Human Megakaryocytes
Tarantino, M. D., Kunicki, T. J., & Nugent, D. J. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb12059.x · Cited by 45 · cited 1×
“Interestingly, megakaryocytes, parental cells of the platelet, express both estrogen and androgen receptors, leading to the speculation that steroids could modulate the expression of enzymes found in the platelet (Tarantino et al., 1994; Khetawat et al., 2000).”
BackgroundXu, Z.-H., Freimuth, R. R., Eckloff, B., Wieben, E., & Weinshilboum, R. M. (2002) · Pharmacogenetics · doi:10.1097/00008571-200201000-00003 · Cited by 40 · cited 12×
“PAPS, the obligatory cosubstrate of sulfotransferases, is synthesized from ATP and inorganic sulfate by a bifunctional enzyme, 30-phosphoadenosine 50-phosphosulfate synthetase (PAPSS).”
BackgroundMethodInfluentialHume, R., Barker, E. V., & Coughtrie, M. W. H. (1996) · Histochemistry and Cell Biology · doi:10.1007/bf01696154 · Cited by 39 · cited 1×
“SULT enzymes have a widespread tissue distribution and are expressed in the liver, lung, brain, skin, platelets, breast, kidney and gastrointestinal tissue (Cappiello et al., 1989; Zou et al., 1990; Kudlacek et al., 1995; Falany and Falany, 1996; Hume et al., 1996).”
BackgroundNing, B., Nowell, S. A., Sweeney, C., Ambrosone, C. B., Williams, S. P., Miao, X., Liang, G., Lin, D., Stone, A., Ratnasinghe, D., et al. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000166823.74378.79 · Cited by 38 · cited 1×
“We have recently described several SNPs in the SULT1A1 promoter region, which are associated with platelet enzymatic activity (Ning et al., 2005).”
BackgroundSelf-citationLi, X., Clemens, D., Cole, & Anderson, R. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1710525 · Cited by 35 · cited 1×
“…highly expressed hepatic sulfotransferase and this isoform has been reported to sulfate a wide variety of phenolic xenobiotics, as well as iodothyronines (Visser et al., 1998; Kester et al., 1999; Li et al., 2001) and the antiangiogenic estrogen metabolite, 2-methoxyestradiol (Spink et al., 2000).”
BackgroundImmunohistochemical Detection of Phenol Sulfotransferase‐Containing Neurons in Human Brain
Zou, J., Pentney, R. J., & Roth, J. A. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb03119.x · Cited by 34 · cited 1×
“SULT enzymes have a widespread tissue distribution and are expressed in the liver, lung, brain, skin, platelets, breast, kidney and gastrointestinal tissue (Cappiello et al., 1989; Zou et al., 1990; Kudlacek et al., 1995; Falany and Falany, 1996; Hume et al., 1996).”
BackgroundSundaram, R. S., Loon, J. A. V., Tucker, R. P., & Weinshilboum, R. M. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.178 · Cited by 27 · cited 2×
“Previously, human platelets have been employed as a source of enzyme for human pharmacogenetic studies due to their expression of two of the most common SULTs, SULT1A1 and SULT1A3 (Sundaram et al., 1989b; Weinshilboum, 1990; Weinshilboum and Aksoy, 1994).”
BackgroundMethodTRANSACTIVATION OF GLUCOCORTICOID-INDUCIBLE RAT ARYL SULFOTRANSFERASE (SULT1A1) GENE TRANSCRIPTION
Fang, H.-L., Shenoy, S. D., Duanmu, Z., Kocarek, T. A., & Runge‐Morris, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1378 · Cited by 21 · cited 1×
“In rodents, Runge-Morris and co-workers demonstrated that expression of SULT1A1 was regulated by glucocorticoids via the glucocorticoid receptor (Duanmu et al., 2001; Fang et al., 2003).”
BackgroundXu, Z.-H., Thomae, B. A., Eckloff, B. W., Wieben, E. D., & Weinshilboum, R. M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00104-7 · Cited by 21 · cited 2×
“The entire coding sequences of both isoforms have been sequenced and functional characterization of identified SNPs have been performed (Xu et al., 2002, 2003).”
BackgroundMethod(1986) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.36.1.42 · Cited by 18
Gender-Related Seasonality of Human Platelet Phenolsulfotransferase Activity
Marazziti, D., Palego, L., Rossi, A., & Cassano, G. B. (1998) · Neuropsychobiology · doi:10.1159/000026509 · Cited by 16 · cited 1×
“Some studies have shown that SULT1A1 platelet enzymatic activity varies by gender and by season (Marazziti et al., 1995, 1998; Nowell et al., 2000).”
BackgroundKudlacek, P. E., Clemens, D. L., & Anderson, R. J. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1670 · Cited by 16 · cited 1×
“SULT enzymes have a widespread tissue distribution and are expressed in the liver, lung, brain, skin, platelets, breast, kidney and gastrointestinal tissue (Cappiello et al., 1989; Zou et al., 1990; Kudlacek et al., 1995; Falany and Falany, 1996; Hume et al., 1996).”
BackgroundKhetawat, G., Faraday, N., Nealen, M. L., et al. (2000) · Blood · doi:10.1182/blood.v95.7.2289.007k03_2289_2296 · Cited by 13
Brittelli, A., Santi, C. D., Raunio, H., Pelkonen, O., Rossi, G., & Pacifici, G. M. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050695 · Cited by 12
Human Platelet Sulfotransferase Shows Seasonal Rhythms
Marazziti, D., Palego, L., Mazzanti, C. M., Silvestri, S., & Cassano, G. B. (1995) · Chronobiology International · doi:10.3109/07420529509064505 · Cited by 12 · cited 1×
“Some studies have shown that SULT1A1 platelet enzymatic activity varies by gender and by season (Marazziti et al., 1995, 1998; Nowell et al., 2000).”
Background
Research works printed but not linked: 2
- Falany CN, Wheeler J, Oh TS, Falany JL . (1994b). J Steroid Biochem Mol Biol 48: 369–375. · DOI · Paper page
- Wilborn T, Lang N, Smith M, Meleth S, Falany C . (2005). J Steroid Biochem Mol Biol, in press.
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Nebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
“intestinal epithelial cells contain a host of cytosolic SULTs, among which are members of the phenol SULT subfamily (SULT1) that are responsible for catalyzing the transfer of a sulfonyl group from 39-phosphoadenosine 59-phosphosulfate to a wide variety of phenolic xenobiotics (Eisenhofer et al., 1999; Nowell and Fala…”
BackgroundThe role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids
Cassidy, A., & Minihane, A.-M. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.136051 · Cited by 508
“with altered drugs responses and sex-steroid concentrations (18, 43).”
BackgroundCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Metadata
- Authors
- Nowell, S., & Falany, C. N.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Nowell, S
- Falany, C N
- Venue
- Oncogene
- Published
- 2006-03-13
- Volume
- 25
- Issue
- 11
- Pages
- 1673-1678
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2058380077
- Semantic Scholar
- 4a231f71813b6ba42e0f4860c32817dcb237908f
- Cited by
- 158
- References
- 49
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 2 · 2018: 5 · 2017: 9 · 2016: 11 · 2015: 4 · 2014: 9 · 2013: 8 · 2012: 15
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- cytosolic sulfotransferases, SULT1A1, SULT2A1, hydroxysteroid sulfotransferase, single nucleotide polymorphisms, genetic variation, cancer risk, drug metabolism, sulfation, 3'-phosphoadenosine 5'-phosphosulfate, personalized treatment, phase II enzymes
- MeSH terms
- Antineoplastic Agents, Black or African American, Ethnicity, Humans, Isoenzymes, Neoplasms, Pharmacogenetics, Sulfotransferases, Arylsulfotransferase, Xenobiotics, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.